The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat distribution, with greater weight loss linked to better outcomes, a study ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

Dear E.M.: Obstructive sleep apnea is when a person stops breathing during sleep due to obstruction of their airway. Some ...